Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1330 views | HTML 4186 views | ?
Theodore Vougiouklakis1, Vassiliki Saloura1, Jae-Hyun Park1, Naofumi Takamatsu2, Takashi Miyamoto2, Yusuke Nakamura1,3 and Yo Matsuo2
1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
2OncoTherapy Science Inc., Kawasaki, Japan
3Department of Surgery, The University of Chicago, Chicago, IL, USA
Yusuke Nakamura, email: [email protected]
Yo Matsuo, email: [email protected]
Keywords: methyltransferase; small-molecule inhibitor; SUV39H2; γ-H2AX
Received: May 05, 2018 Accepted: June 01, 2018 Published: August 07, 2018
Protein methyltransferase SUV39H2 was reported to methylate histone H2AX at lysine 134 and enhance the formation of phosphorylated H2AX (γ-H2AX), which causes chemoresistance of cancer cells. We found that a series of imidazo[1,2-a]pyridine compounds that we synthesized could inhibit SUV39H2 methyltransferase activity. One of the potent compounds, OTS193320, was further analyzed in in vitro studies. The compound decreased global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggered apoptotic cell death. Combination of OTS193320 with doxorubicin (DOX) resulted in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX. Further optimization of inhibitors and their in vivo analysis identified a compound, OTS186935, which revealed significant inhibition of tumor growth in mouse xenograft models using MDA-MB-231 breast cancer cells and A549 lung cancer cells without any detectable toxicity. Our results suggest that the SUV39H2 inhibitors sensitize cancer cells to DOX by reduction of γ-H2AX levels in cancer cells, and collectively demonstrate that SUV39H2 inhibition warrants further investigation as a novel anti-cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.